Galway based medtech company Aerogen has crossed a titanic milestone having now produced 20 million of their drug delivery systems.
The Aerogen Solo is used by hospitals and caregivers around the world to aerosolise drugs for the acutely compromised respiratory patient.
This milestone is jointly celebrated with the company’s 25th anniversary. Founded above a butchers shop in Galway in 1997, Aerogen is now Ireland’s largest indigenous medtech company.
Headquartered in Galway with manufacturing in Parkmore and Shannon, Aerogen’s workforce has tripled in the past five years to 500 employees operating in 28 countries.
The expansion has continued in recent years, with the company bringing on 110 new employees in 2023, and a further 50 multi-disciplined positions in the pipeline.
Speaking at Aerogen’s milestone event at their plant in Parkmore, Minister Neale Richmond TD said: “I am delighted to join Aerogen at their highly impressive facility here in Galway to witness the production of the 20 millionth Aerogen Solo device.”
“Irish businesses like Aerogen are the backbone of our economy, scaling and growing their footprint overseas, while continuing to develop and nurture the team back home.”
The Minister added that he is delighted that Aerogen has grown to become, “An international player on the world stage working with and developing lifesaving respiratory devices and clinical products for the health sector globally.”
The 20 millionth Aerogen Solo was packaged in a unique, gold branded box. The customer that receives this shipment will be acknowledged with a €10,000 donation to the charity of their choice.
As part of their 25th-anniversary celebration, Aerogen has planned a series of 25 events and initiatives to express its gratitude to its employees, customers and the communities in which they operate.
The company has donated over €100,000 to various charities and organisations already this year with plenty more activity planned.
The 20 millionth product is an incredible milestone for us to achieve during our 25 year celebrations” said John Power, Aerogen CEO and Founder.
“Our journey has been marked by relentless dedication to innovation led and customer-centric solutions and whilst we today rightly celebrate a production milestone, we also reflect on the acutely sick patients those products have played a key role in treating.”
“To be able to impact the clinical outcome for one person is a great privilege, to be involved in the treatment of 20 million individual patients globally is not alone a huge privilege but also an incredible honour for us all at Aerogen”.
Aerogen’s parent company Stamford Devices Limited Group, reported a strong financial performance for the year ending December 2022, recording €119.9 million in revenue.
Sales in Aerogen’s core Medical Device business of €117 million resulted in pre-tax earnings of €26.5 million.
